Novadaq buys fluoro endoscopy technology:
This article was originally published in Clinica
Executive Summary
Toronto-based developer of real-time medical imaging systems Novadaq Technologies is to acquire certain business assets, including a portfolio of fluorescence endoscopy patents, from fellow Canadian medical device company Xillix Technologies. Under the terms of the agreement, Novadaq will pay Xillix Can$3m ($2.7m) on closing, in exchange for the latter's auto-fluorescence and multi-modal imaging portfolio of 31 issued patents and multiple pending patents in the US, Japan and Europe. The purchase also includes the rights to Xillix's pipeline fluorescence imaging technologies. The transaction is slated to close in early May.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.